Laura Mitic, PhD, is the President of the Bluefield Project to Cure Frontotemporal Dementia, a San Francisco-based 501(c)(3) nonprofit dedicated to accelerating the development of treatments for frontotemporal dementia caused by mutations in progranulin (GRN-FTD). Bluefield funds a consortium of researchers at academic institutions across the US, Europe, and South America to advance our understanding of GRN-FTD.

Dr. Mitic oversees the Neurofilament Surveillance Project, an ALLFTD ancillary study and multi-year pre-competitive collaboration with biotech, pharma, and nonprofits to better understand the clinical utility of measuring plasma neurofilament light chain in genetic FTD. She also works across diverse collaborative initiatives to help foster the success of clinical trials in progranulin-deficient FTD, including efforts to identify more trial participants and to decrease barriers to clinical trial participation, such as the Progranulin Information Navigator.

Dr. Mitic earned a BA from Northwestern University and a PhD in cell biology from Yale University, and completed postdoctoral studies in the genetics of aging at UCSF.